This inventor holds 1 USPTO granted patent. Top assignee: University System of Maryland. Active years: 2019.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2019
Title: Mark Hoofnagle: Innovator in Ischemia Treatment
Introduction
Mark Hoofnagle is a notable inventor based in Baltimore, MD (US). He has made significant contributions to the field of medical treatment, particularly in the area of ischemia-induced angiogenesis and arteriogenesis. His innovative approach focuses on the inhibition of p53, a potent inhibitor of angiogenesis and arteriogenesis.
Latest Patents
Mark Hoofnagle holds a patent for "Methods of treatment of ischemia-induced angiogenesis and arteriogenesis." This patent outlines methods for treating diabetic-induced ischemia by locally administering a therapeutically effective amount of one or more p53 molecule inhibitors or their analogs and derivatives to ischemic tissue. The methods aim to improve limb perfusion and enhance ischemia-induced angiogenesis and arteriogenesis in subjects in need.
Career Highlights
Mark Hoofnagle is affiliated with the University System of Maryland, where he continues to advance his research and innovations. His work has the potential to significantly impact the treatment of ischemic conditions, providing new avenues for improving patient outcomes.
Collaborations
He has collaborated with notable colleagues such as Rajabrata Sarkar and Subhradip Mukhopadhyay, contributing to a rich environment of innovation and research.
Conclusion
Mark Hoofnagle's work in the field of ischemia treatment exemplifies the importance of innovation in medical science. His patent and ongoing research hold promise for improving the lives of those affected by ischemic conditions.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile